Population pharmacokinetic and pharmacodynamic analysis in allergic diseases
- PMID: 19601723
- DOI: 10.1080/10837450902891543
Population pharmacokinetic and pharmacodynamic analysis in allergic diseases
Abstract
In this chapter, we introduce the concepts and methodologies of population analysis as applied to analyzing pharmacokinetic and pharmacodynamic data. One of the key determining characteristics of the population approach is that through it, one seeks not only to characterize deterministic trends in the data, but also to identify and estimate the magnitudes of the important sources of variability within the data. The first section of this chapter provides an introduction to the primary concepts of, and motivation for, population modeling by way of a hypothetical case study. Then, the various methodologies that have been employed throughout the history of population analysis are described in further detail. Of these, the most commonly employed today is nonlinear mixed-effects (NLME) modeling. Finally, notable examples of the application of population PK and PK/PD modeling to treatments for allergies and asthma are discussed. Population PK models have frequently been used to extrapolate exposures to special populations, such as pediatrics, as well as to optimize treatment regimens and trial designs for these populations. Population PK/PD models have most frequently been applied to analyzing and interpreting data from wheal and flare trials, but are also becoming increasingly important in the analysis of PD data from monoclonal antibodies.
Similar articles
-
Therapeutic management of allergic diseases.Drug Metab Rev. 2009;41(3):301-43. doi: 10.1080/10837450902891204. Drug Metab Rev. 2009. PMID: 19601717 Review.
-
From pharmacokinetics to therapeutics.Drug Metab Rev. 2009;41(3):455-74. doi: 10.1080/10837450902891535. Drug Metab Rev. 2009. PMID: 19601722 Review.
-
Pharmacokinetics in special populations.Drug Metab Rev. 2009;41(3):422-54. doi: 10.1080/10837450902891527. Drug Metab Rev. 2009. PMID: 19601721 Review.
-
Population pharmacodynamic and pharmacokinetic modeling via mixed effects.Curr Opin Drug Discov Devel. 2000 May;3(3):314-30. Curr Opin Drug Discov Devel. 2000. PMID: 19649865
-
Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.Drug Discov Today. 2009 Mar;14(5-6):316-20. doi: 10.1016/j.drudis.2008.11.004. Epub 2008 Dec 26. Drug Discov Today. 2009. PMID: 19059496 Review.
Cited by
-
Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?Antibiotics (Basel). 2021 Apr 29;10(5):507. doi: 10.3390/antibiotics10050507. Antibiotics (Basel). 2021. PMID: 33946905 Free PMC article. Review.
-
Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection.Clin Pharmacol Ther. 2019 Dec;106(6):1319-1327. doi: 10.1002/cpt.1543. Epub 2019 Aug 23. Clin Pharmacol Ther. 2019. PMID: 31194885 Free PMC article. Clinical Trial.
-
Computation of nonparametric, mixed effects, maximum likelihood, biosensor data based-estimators for the distributions of random parameters in an abstract parabolic model for the transdermal transport of alcohol.Math Biosci Eng. 2023 Nov 9;20(11):20345-20377. doi: 10.3934/mbe.2023900. Math Biosci Eng. 2023. PMID: 38052648 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical